Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hylan is a chemically modified, cross-linked derivative of hyaluronan (hyaluronic acid) designed to enhance the viscoelastic properties and molecular weight of the native polysaccharide. By cross-linking the hyaluronan chains, hylan achieves greater viscosity and stability while maintaining the biocompatibility and non-immunogenicity of the original molecule. In the context of ophthalmology and orbital surgery, specifically researched by **Amsterdam UMC**, hylan A is utilized as a viscoadaptive lubricant in eye drop formulations. Its primary mechanism involves providing a long-lasting, protective moisture film that reduces mechanical friction between an ocular prosthesis and the conjunctival socket. This reduction in friction is critical for treating ocular prosthesis-related discomfort and chronic mucopurulent discharge in anophthalmic patients, where traditional lubricants often fail due to rapid drainage or insufficient cushioning.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hylan.